Analysis of177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 505-511

  Denoyer, Delphine ^a,b   Lobachevsky, Pavel ^a,c   Jackson, Price ^a   Thompson, Mick ^a   Martin, Olga A ^a   Hicks, Rodney J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

177lu octreotate; Dna damage; Prrt; normal tissue toxicity; h2ax

Indexed keywords

GAMMA HISTONE H2AX; HISTONE H2AX; LUTENIUM DOTA OCTREOTATE LU 77; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; 177LU-OCTREOTATE; H2AFX PROTEIN, HUMAN; HISTONE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BONE MARROW; CANCER RADIOTHERAPY; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DOSIMETRY; FEMALE; HUMAN; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RADIOACTIVITY; SPLEEN; TREATMENT RESPONSE; TREND STUDY; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; DOUBLE STRANDED DNA BREAK; FLUORESCENCE MICROSCOPY; KINETICS; METABOLISM; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; RADIATION RESPONSE; RADIOMETRY; TIME;

ADULT; AGED; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; FEMALE; HISTONES; HUMANS; KINETICS; LYMPHOCYTES; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLATION; RADIOMETRY; RECEPTORS, PEPTIDE; TIME FACTORS;

EID: 84928233290     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.145581     Document Type: Article

References (31)

1. Barber TW, Hofman MS, Thomson BN, Hicks RJ. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38:64-71.
2. Modlin IM, Moss SF, Oberg K, et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust. 2010;193:46-52.
3. 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50-56.
4. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5-19.
5. 177Lu-DOTA. J Clin Oncol. 2008;26:2124-2130.
6. Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957-967.
7. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 2012;327:123-133.
8. Redon CE, Weyemi U, Parekh PR, Huang D, Burrell AS, Bonner WM. Gamma-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta. 2012;1819:743-756.
9. Ghardi M, Moreels M, Chatelain B, Chatelain C, Baatout S. Radiation-induced double strand breaks and subsequent apoptotic DNA fragmentation in human peripheral blood mononuclear cells. Int J Mol Med. 2012;29:769-780.
10. Redon CE, Dickey JS, Bonner WM, Sedelnikova OA. Gamma-H2AX as a biomarker of DNA damage induced by ionizing radiation in human peripheral blood lymphocytes and artificial skin. Adv Space Res. 2009;43:1171-1178.
11. Redon CE, Dickey JS, Nakamura AJ, et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci USA. 2010;107:17992-17997.
12. Redon CE, Nakamura AJ, Sordet O, et al. γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol Biol. 2011;682:249-270.
13. Sak A, Grehl S, Erichsen P, et al. Gamma-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol. 2007;83:639-652.
14. Adams G, Martin OA, Roos DE, et al. Enhanced intrinsic radiosensitivity after treatment with stereotactic radiosurgery for an acoustic neuroma. Radiother Oncol. 2012;103:410-414.
15. Van Oorschot B, Oei AL, Nuijens AC, et al. Decay of gamma-H2AX foci correlates with potentially lethal damage repair and P53 status in human colorectal carcinoma cells. Cell Mol Biol Lett. 2014;19:37-51.
16. Doai M, Watanabe N, Takahashi T, et al. Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using gamma-H2AX foci of DNA damage in lymphocytes. Ann Nucl Med. 2013;27:233-238.
17. Lassmann M, Hanscheid H, Gassen D, et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2010;51:1318-1325.
18. 18F-FDG PET/CT examinations. Eur J Nucl Med Mol Imaging. 2012;39:1712-1719.
19. Andrievski A, Wilkins RC. The response of gamma-H2AX in human lymphocytes and lymphocytes subsets measured in whole blood cultures. Int J Radiat Biol. 2009;85:369-376.
20. MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to x-rays. Int J Radiat Biol. 2003;79:351-358.
21. Rothkamm K, Horn S. Gamma-H2AX as protein biomarker for radiation exposure. Ann Ist Super Sanita. 2009;45:265-271.
22. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA. 2003;100:5057-5062.
23. Zwicker F, Swartman B, Sterzing F, et al. Biological in-vivo measurement of dose distribution in patients' lymphocytes by gamma-H2AX immunofluorescence staining: 3D conformal- vs. step-and-shoot IMRT of the prostate gland. Radiat Oncol. 2011;6:62.
24. 90Y-DOTATOC. Cancer Biother Radiopharm. 2009;24:659-665.
25. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009;9:351-360.
26. Adamsen BL, Kravik KL, De Angelis PM. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. Int J Oncol. 2011;39:673-682.
27. Ikeda M, Kurose A, Takatori E, et al. DNA damage detected with γH2AX in endometrioid adenocarcinoma cell lines. Int J Oncol. 2010;36:1081-1088.
28. Sánchez-Su árez P, Ostrosky-Wegman P, Gallegos-Hernández F, et al. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res. 2008;640:8-15.
29. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302-311.
30. Zhou T, Hasty P, Walter CA, Bishop AJ, Scott LM, Rebel VI. Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA? Exp Hematol. 2013;41:665-674.
31. Kefala M, Papageorgiou SG, Kontos CK, et al. Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes. Leuk Res. 2013;37:1576-1582.